Amyotrophic Lateral Sclerosis (ALS) Treatment Market Report

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Study Report 2022 Historical Trends, Growth, and Forecast to 2028

  • POSTDATE：Mar 01, 2022
  • PAGES：230
  • REPORT CODE：GMM788459
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • Amyotrophic Lateral Sclerosis (ALS) Treatment market report explains the definition, types, applications, major countries, and major players of the Amyotrophic Lateral Sclerosis (ALS) Treatment market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.

    The report contains qualitative and quantitative analysis of the entire industry.

    The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.

    By Player:

    • Sun Pharma

    • Glemark Generics

    • Mitsubishi Tanabe Pharma

    • Lunan Pharma

    • Apotex

    • Sanofi

    • Covis Pharma

    • Mylan Pharma

    By Type:

    • Riluzole

    • Edaravone (Radicava)

    • Other

    By End-User:

    • Hospital

    • Drugs Store

    • Other

    By Region:

    North America

    • United States

    • Canada

    • Mexico

    Europe

    • Germany

    • UK

    • Spain

    • France

    • Italy

    • Denmark

    • Finland

    • Norway

    • Sweden

    • Poland

    • Russia

    • Turkey

    Asia-Pacific

    • China

    • Japan

    • India

    • South Korea

    • Pakistan

    • Bangladesh

    • Indonesia

    • Thailand

    • Singapore

    • Malaysia

    • Philippines

    • Vietnam

    • Others

    South America

    • Brazil

    • Colombia

    • Chile

    • Argentina

    • Venezuela

    • Peru

    • Puerto Rico

    • Ecuador

    • Others

    GCC

    • Bahrain

    • Kuwait

    • Oman

    • Qatar

    • Saudi Arabia

    • United Arab Emirates

    Africa

    • Nigeria

    • South Africa

    • Egypt

    • Algeriat

    • Others

    Oceania

    • Australia

    • New Zealand

  • TABLE OF CONTENT

    1. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Executive Summary

    • 1.1 Introduction

    • 1.2 Market Panorama, 2022

    2 Coronavirus Impact

    • 2.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Outlook to 2028- Original Forecasts

    • 2.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Outlook to 2028- COVID-19 Affected Forecasts

    • 2.3 Impact on Industry

    3 Strategic Analytics to Boost Productivity and Profitability

    • 3.1 Potential Market Drivers and Opportunities

    • 3.2 New Challenges and Strategies

    • 3.3 Short Term and Long Term Amyotrophic Lateral Sclerosis (ALS) Treatment Market Trends

    4 Key Inferences

    5 Market Overview

    • 5.1 Current Market Scenario

    • 5.2 Porter's Five Forces Analysis

      • 5.2.1 Bargaining Power of Suppliers

      • 5.2.2 Bargaining Power of Consumers

      • 5.2.3 Threat of New Entrants

      • 5.2.4 Threat of Substitute Product and Services

      • 5.2.5 Competitive Rivalry within the Industry

    6 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market- Recent Developments

    • 6.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Market News and Developments

    • 6.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Deals Landscape

    7 Amyotrophic Lateral Sclerosis (ALS) Treatment Raw Materials and Cost Structure Analysis

    • 7.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Raw Materials

    • 7.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Price Trend of Key Raw Materials

    • 7.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Key Suppliers of Raw Materials

    • 7.4 Amyotrophic Lateral Sclerosis (ALS) Treatment Market Concentration Rate of Raw Materials

    • 7.5 Amyotrophic Lateral Sclerosis (ALS) Treatment Cost Structure Analysis

      • 7.5.1 Amyotrophic Lateral Sclerosis (ALS) Treatment Raw Materials Analysis

      • 7.5.2 Amyotrophic Lateral Sclerosis (ALS) Treatment Labor Cost Analysis

      • 7.5.3 Amyotrophic Lateral Sclerosis (ALS) Treatment Manufacturing Expenses Analysis

    8 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Import and Export Analysis (Top 10 Countries)

    • 8.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • 8.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Export by Region (Top 10 Countries) (2017-2028)

    9 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook by Types and Applications to 2022

    • 9.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate by Type (2017-2022)

      • 9.1.1 Global Riluzole Consumption and Growth Rate (2017-2022)

      • 9.1.2 Global Edaravone (Radicava) Consumption and Growth Rate (2017-2022)

      • 9.1.3 Global Other Consumption and Growth Rate (2017-2022)

    • 9.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate by Application (2017-2022)

      • 9.2.1 Global Hospital Consumption and Growth Rate (2017-2022)

      • 9.2.2 Global Drugs Store Consumption and Growth Rate (2017-2022)

      • 9.2.3 Global Other Consumption and Growth Rate (2017-2022)

    10 Region and Country-wise Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Outlook till 2022

    • 10.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    • 10.2 North America Consumption Analysis

      • 10.2.1 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.2.2 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.2.3 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    • 10.3 Europe Consumption Analysis

      • 10.3.1 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.2 UK Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.3 Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.4 Belgium Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.5 France Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.7 Denmark Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.8 Finland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.9 Norway Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.10 Sweden Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.11 Poland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.12 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.3.13 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    • 10.4 APAC Consumption Analysis

      • 10.4.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.2 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.3 India Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.5 Pakistan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.6 Bangladesh Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.7 Indonesia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.8 Thailand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.9 Singapore Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.10 Malaysia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.11 Philippines Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.4.12 Vietnam Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    • 10.5 South America Consumption Analysis

      • 10.5.1 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.5.2 Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.5.3 Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.5.4 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.5.5 Venezuela Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.5.6 Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.5.7 Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.5.8 Ecuador Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    • 10.6 GCC Consumption Analysis

      • 10.6.1 Bahrain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.6.2 Kuwait Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.6.3 Oman Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.6.4 Qatar Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.6.5 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.6.6 United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    • 10.7 Africa Consumption Analysis

      • 10.7.1 Nigeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.7.2 South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.7.3 Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.7.4 Algeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    • 10.8 Oceania Consumption Analysis

      • 10.8.1 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

      • 10.8.2 New Zealand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption (2017-2022)

    11 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Competitive Analysis

    • 11.1 Sun Pharma

      • 11.1.1 Sun Pharma Company Details

      • 11.1.2 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.1.3 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.1.4 Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.1.5 Recent Research and Development Strategies

    • 11.2 Glemark Generics

      • 11.2.1 Glemark Generics Company Details

      • 11.2.2 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.2.3 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.2.4 Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.2.5 Recent Research and Development Strategies

    • 11.3 Mitsubishi Tanabe Pharma

      • 11.3.1 Mitsubishi Tanabe Pharma Company Details

      • 11.3.2 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.3.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.3.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.3.5 Recent Research and Development Strategies

    • 11.4 Lunan Pharma

      • 11.4.1 Lunan Pharma Company Details

      • 11.4.2 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.4.3 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.4.4 Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.4.5 Recent Research and Development Strategies

    • 11.5 Apotex

      • 11.5.1 Apotex Company Details

      • 11.5.2 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.5.3 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.5.4 Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.5.5 Recent Research and Development Strategies

    • 11.6 Sanofi

      • 11.6.1 Sanofi Company Details

      • 11.6.2 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.6.3 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.6.4 Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.6.5 Recent Research and Development Strategies

    • 11.7 Covis Pharma

      • 11.7.1 Covis Pharma Company Details

      • 11.7.2 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.7.3 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.7.4 Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.7.5 Recent Research and Development Strategies

    • 11.8 Mylan Pharma

      • 11.8.1 Mylan Pharma Company Details

      • 11.8.2 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

      • 11.8.3 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

      • 11.8.4 Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

      • 11.8.5 Recent Research and Development Strategies

    12 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook by Types and Applications to 2028

    • 12.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate by Type (2022-2028)

      • 12.1.1 Global Riluzole Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.2 Global Edaravone (Radicava) Consumption Forecast and Growth Rate (2022-2028)

      • 12.1.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    • 12.2 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate by Application (2022-2028)

      • 12.2.1 Global Hospital Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.2 Global Drugs Store Consumption Forecast and Growth Rate (2022-2028)

      • 12.2.3 Global Other Consumption Forecast and Growth Rate (2022-2028)

    13 Country-wise Amyotrophic Lateral Sclerosis (ALS) Treatment Market Analysis and Outlook to 2028

    • 13.1 Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    • 13.2 North America Consumption Analysis

      • 13.2.1 United States Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.2.2 Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.2.3 Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    • 13.3 Europe Consumption Analysis

      • 13.3.1 Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.2 UK Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.3 Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.4 Belgium Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.5 France Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.6 Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.7 Denmark Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.8 Finland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.9 Norway Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.10 Sweden Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.11 Poland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.12 Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.3.13 Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    • 13.4 APAC Consumption Analysis

      • 13.4.1 China Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.2 Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.3 India Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.4 South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.5 Pakistan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.6 Bangladesh Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.7 Indonesia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.8 Thailand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.9 Singapore Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.10 Malaysia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.11 Philippines Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.4.12 Vietnam Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    • 13.5 South America Consumption Analysis

      • 13.5.1 Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.5.2 Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.5.3 Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.5.4 Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.5.5 Venezuela Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.5.6 Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.5.7 Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.5.8 Ecuador Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    • 13.6 GCC Consumption Analysis

      • 13.6.1 Bahrain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.6.2 Kuwait Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.6.3 Oman Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.6.4 Qatar Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.6.5 Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.6.6 United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    • 13.7 Africa Consumption Analysis

      • 13.7.1 Nigeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.7.2 South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.7.3 Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.7.4 Algeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    • 13.8 Oceania Consumption Analysis

      • 13.8.1 Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

      • 13.8.2 New Zealand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast (2022-2028)

    14 Conclusions


    The List of Tables and Figures

    • Table Definition of Amyotrophic Lateral Sclerosis (ALS) Treatment

    • Figure of Amyotrophic Lateral Sclerosis (ALS) Treatment Picture

    • Table Global Amyotrophic Lateral Sclerosis (ALS) Treatment Import by Region (Top 10 Countries) (2017-2028)

    • Table Global Amyotrophic Lateral Sclerosis (ALS) Treatment Export by Region (Top 10 Countries) (2017-2028)

    • Figure Global Riluzole Consumption and Growth Rate (2017-2022)

    • Figure Global Edaravone (Radicava) Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Hospital Consumption and Growth Rate (2017-2022)

    • Figure Global Drugs Store Consumption and Growth Rate (2017-2022)

    • Figure Global Other Consumption and Growth Rate (2017-2022)

    • Figure Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Table North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Figure United States Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Figure Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure UK Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Belgium Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure France Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Denmark Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Finland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Norway Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Sweden Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Poland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Table APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Figure China Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure India Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Pakistan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Bangladesh Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Indonesia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Thailand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Singapore Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Malaysia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Philippines Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Vietnam Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Table South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Figure Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Venezuela Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Ecuador Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Table GCC Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Figure Bahrain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Kuwait Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Oman Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Qatar Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Figure Nigeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure Algeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Oceania Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption by Country (2017-2022)

    • Figure Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Figure New Zealand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption and Growth Rate (2017-2022)

    • Table Sun Pharma Company Details

    • Table Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Sun Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Table Glemark Generics Company Details

    • Table Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Glemark Generics Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Table Mitsubishi Tanabe Pharma Company Details

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Table Lunan Pharma Company Details

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Lunan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Table Apotex Company Details

    • Table Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Apotex Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Table Sanofi Company Details

    • Table Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Sanofi Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Table Covis Pharma Company Details

    • Table Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Covis Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Table Mylan Pharma Company Details

    • Table Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Sales, Price, Value and Gross Profit (2017-2022)

    • Table Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Main Business and Markets Served

    • Table Mylan Pharma Amyotrophic Lateral Sclerosis (ALS) Treatment Product Portfolio

    • Figure Global Riluzole Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Edaravone (Radicava) Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Hospital Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Drugs Store Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Other Consumption Forecast and Growth Rate (2022-2028)

    • Figure Global Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Table North America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure United States Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure UK Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Belgium Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure France Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Denmark Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Finland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Norway Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Sweden Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Poland Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Turkey Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure China Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure India Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Pakistan Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Bangladesh Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Indonesia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Thailand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Singapore Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Malaysia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Philippines Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Vietnam Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table South America Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Colombia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Venezuela Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Peru Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Puerto Rico Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Ecuador Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table GCC Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Bahrain Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Kuwait Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Oman Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Qatar Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure United Arab Emirates Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Nigeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Egypt Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure Algeria Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Table Oceania Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast by Country (2022-2028)

    • Figure Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

    • Figure New Zealand Amyotrophic Lateral Sclerosis (ALS) Treatment Consumption Forecast and Growth Rate (2022-2028)

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US